{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T19:11:10Z","timestamp":1787944270422,"version":"build-2784847793"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003092","name":"Diabetes Fonds","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003092","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011570","name":"Stichting Diabetes Onderzoek Nederland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011570","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Wanek Family Project for Type 1 Diabetes"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Aims\/hypothesis<\/jats:title>\n<jats:p>Heterogeneity in individuals with type 1 diabetes has become more generally appreciated, but has not yet been extensively and systematically characterised. Here, we aimed to characterise type 1 diabetes heterogeneity by creating immunological, genetic and clinical profiles for individuals with juvenile-onset type 1 diabetes in a cross-sectional study.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Participants were HLA-genotyped to determine <jats:italic>HLA-DR-DQ<\/jats:italic> risk, and SNP-genotyped to generate a non-HLA genetic risk score (GRS) based on 93 type 1 diabetes-associated SNP variants outside the MHC region. Islet autoimmunity was assessed as T cell proliferation upon stimulation with the beta cell antigens GAD65, islet antigen-2 (IA-2), preproinsulin (PPI) and defective ribosomal product of the insulin gene (INS-DRIP). Clinical parameters were collected retrospectively.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Of 80 individuals, 67 had proliferation responses to one or more islet antigens, with vast differences in the extent of proliferation. Based on the multitude and amplitude of the proliferation responses, individuals were clustered into non-, intermediate and high responders. High responders could not be characterised entirely by enrichment for the highest risk HLA-<jats:italic>DR3-DQ2\/DR4-DQ8<\/jats:italic> genotype. However, high responders did have a significantly higher non-HLA GRS. Clinically, high T cell responses to beta cell antigens did not reflect in worsened glycaemic control, increased complications, development of associated autoimmunity or younger age at disease onset. The number of beta cell antigens that an individual responded to increased with disease duration, pointing to chronic islet autoimmunity and epitope spreading.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions\/interpretation<\/jats:title>\n<jats:p>Collectively, these data provide new insights into type 1 diabetes disease heterogeneity and highlight the importance of stratifying patients on the basis of their genetic and autoimmune signatures for immunotherapy and personalised disease management.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s00125-019-05032-3","type":"journal-article","created":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T13:05:42Z","timestamp":1576242342000},"page":"351-361","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Clinical and genetic correlates of islet-autoimmune signatures in juvenile-onset type 1 diabetes"],"prefix":"10.1007","volume":"63","author":[{"given":"Laura A.","family":"Claessens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris","family":"Wesselius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menno","family":"van Lummel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Laban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flip","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick","family":"Mul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Nikolic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk-Jan","family":"Aanstoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobby P. C.","family":"Koeleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart O.","family":"Roep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,21]]},"reference":[{"issue":"2","key":"5032_CR1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2217\/imt.14.104","volume":"7","author":"NJ Woittiez","year":"2015","unstructured":"Woittiez NJ, Roep BO (2015) Impact of disease heterogeneity on treatment efficacy of immunotherapy in type 1 diabetes: different shades of gray. Immunotherapy 7(2):163\u2013174","journal-title":"Immunotherapy."},{"issue":"9911","key":"5032_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0140-6736(13)60591-7","volume":"383","author":"Mark A Atkinson","year":"2014","unstructured":"Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet 383(9911):69\u201382","journal-title":"The Lancet"},{"issue":"5","key":"5032_CR3","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/sj.gene.6364106","volume":"5","author":"BP Koeleman","year":"2004","unstructured":"Koeleman BP, Lie BA, Undlien DE et al (2004) Genotype effects and epistasis in type 1 diabetes and HLA-DQ trans dimer associations with disease. Genes Immun 5(5):381\u2013388","journal-title":"Genes Immun"},{"issue":"4","key":"5032_CR4","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.2337\/db07-1331","volume":"57","author":"H Erlich","year":"2008","unstructured":"Erlich H, Valdes AM, Noble J et al (2008) HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes 57(4):1084\u20131092","journal-title":"Diabetes"},{"issue":"6","key":"5032_CR5","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s11892-011-0223-x","volume":"11","author":"JA Noble","year":"2011","unstructured":"Noble JA, Valdes AM (2011) Genetics of the HLA region in the prediction of type 1 diabetes. Curr Diab Rep 11(6):533\u2013542","journal-title":"Curr Diab Rep"},{"issue":"4","key":"5032_CR6","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/ng.3245","volume":"47","author":"S Onengut-Gumuscu","year":"2015","unstructured":"Onengut-Gumuscu S, Chen W-M, Burren O et al (2015) Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers. Nat Genet 47(4):381\u2013386","journal-title":"Nat Genet"},{"issue":"9","key":"5032_CR7","doi-asserted-by":"publisher","first-page":"e1002293","DOI":"10.1371\/journal.pgen.1002293","volume":"7","author":"JP Bradfield","year":"2011","unstructured":"Bradfield JP, Qu H-Q, Wang K et al (2011) A genome-wide meta-analysis of six type 1 diabetes cohorts identifies multiple associated loci. PLoS Genet 7(9):e1002293","journal-title":"PLoS Genet"},{"issue":"6","key":"5032_CR8","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/ng.381","volume":"41","author":"JC Barrett","year":"2009","unstructured":"Barrett JC, Clayton DG, Concannon P et al (2009) Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 41(6):703\u2013707","journal-title":"Nat Genet"},{"issue":"7","key":"5032_CR9","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/ng2068","volume":"39","author":"JA Todd","year":"2007","unstructured":"Todd JA, Walker NM, Cooper JD et al (2007) Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 39(7):857\u2013864","journal-title":"Nat Genet"},{"issue":"12","key":"5032_CR10","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1038\/ng.249","volume":"40","author":"JD Cooper","year":"2008","unstructured":"Cooper JD, Smyth DJ, Smiles AM et al (2008) Meta-analysis of genome-wide association study data identifies additional type 1 diabetes risk loci. Nat Genet 40(12):1399\u20131401","journal-title":"Nat Genet"},{"issue":"9","key":"5032_CR11","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41588-018-0183-z","volume":"50","author":"AV Khera","year":"2018","unstructured":"Khera AV, Chaffin M, Aragam KG et al (2018) Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet 50(9):1219\u20131224","journal-title":"Nat Genet"},{"issue":"12","key":"5032_CR12","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1007\/s00125-014-3362-1","volume":"57","author":"C Winkler","year":"2014","unstructured":"Winkler C, Krumsiek J, Buettner F et al (2014) Feature ranking of type 1 diabetes susceptibility genes improves prediction of type 1 diabetes. Diabetologia 57(12):2521\u20132529","journal-title":"Diabetologia"},{"issue":"3","key":"5032_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2337\/dc15-1111","volume":"39","author":"RA Oram","year":"2016","unstructured":"Oram RA, Patel K, Hill A et al (2016) A type 1 diabetes genetic risk score can aid discrimination between type 1 and type 2 diabetes in young adults. Diabetes Care 39(3):337\u2013344","journal-title":"Diabetes Care"},{"issue":"7","key":"5032_CR14","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.2337\/db15-1690","volume":"65","author":"KA Patel","year":"2016","unstructured":"Patel KA, Oram RA, Flanagan SE et al (2016) Type 1 diabetes genetic risk score: a novel tool to discriminate monogenic and type 1 diabetes. Diabetes 65(7):2094\u20132099","journal-title":"Diabetes"},{"issue":"1","key":"5032_CR15","doi-asserted-by":"publisher","first-page":"4529","DOI":"10.1038\/s41598-018-22574-5","volume":"8","author":"DJ Perry","year":"2018","unstructured":"Perry DJ, Wasserfall CH, Oram RA et al (2018) Application of a genetic risk score to racially diverse type 1 diabetes populations demonstrates the need for diversity in risk-modeling. Sci Rep 8(1):4529","journal-title":"Sci Rep"},{"key":"5032_CR16","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.2337\/dc18-0087","volume":"41","author":"MJ Redondo","year":"2018","unstructured":"Redondo MJ, Geyer S, Steck AK et al (2018) A type 1 diabetes genetic risk score predicts progression of islet autoimmunity and development of type 1 diabetes in individuals at risk. Diabetes Care 41:1887\u20131894","journal-title":"Diabetes Care"},{"issue":"4","key":"5032_CR17","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nm.4289","volume":"23","author":"MJL Kracht","year":"2017","unstructured":"Kracht MJL, van Lummel M, Nikolic T et al (2017) Autoimmunity against a defective ribosomal insulin gene product in type 1 diabetes. Nat Med 23(4):501\u2013507","journal-title":"Nat Med"},{"issue":"1","key":"5032_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1006\/prep.1999.1162","volume":"18","author":"KL Franken","year":"2000","unstructured":"Franken KL, Hiemstra HS, van Meijgaarden KE et al (2000) Purification of his-tagged proteins by immobilized chelate affinity chromatography: the benefits from the use of organic solvent. Protein Expr Purif 18(1):95\u201399","journal-title":"Protein Expr Purif"},{"issue":"4","key":"5032_CR19","doi-asserted-by":"publisher","first-page":"988","DOI":"10.2337\/dc10-1903","volume":"34","author":"DM Tridgell","year":"2011","unstructured":"Tridgell DM, Spiekerman C, Wang RS, Greenbaum CJ (2011) Interaction of onset and duration of diabetes on the percent of GAD and IA-2 antibody\u2013positive subjects in the type 1 diabetes genetics consortium database. Diabetes Care 34(4):988\u2013993","journal-title":"Diabetes Care"},{"issue":"11","key":"5032_CR20","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1007\/s00125-005-1949-2","volume":"48","author":"JJ Meier","year":"2005","unstructured":"Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC (2005) Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Diabetologia 48(11):2221\u20132228","journal-title":"Diabetologia"},{"issue":"11","key":"5032_CR21","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.2337\/db10-0676","volume":"59","author":"HA Keenan","year":"2010","unstructured":"Keenan HA, Sun JK, Levine J et al (2010) Residual insulin production and pancreatic ss-cell turnover after 50 years of diabetes: Joslin medalist study. Diabetes. 59(11):2846\u20132853","journal-title":"Diabetes."},{"key":"5032_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jaut.2015.05.005","volume":"61","author":"J Lempainen","year":"2015","unstructured":"Lempainen J, Laine AP, Hammais A et al (2015) Non-HLA gene effects on the disease process of type 1 diabetes: from HLA susceptibility to overt disease. J Autoimmun 61:45\u201353","journal-title":"J Autoimmun"},{"issue":"5","key":"5032_CR23","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.2337\/db14-1497","volume":"64","author":"C Torn","year":"2015","unstructured":"Torn C, Hadley D, Lee HS et al (2015) Role of type 1 diabetes-associated SNPs on risk of autoantibody positivity in the TEDDY study. Diabetes. 64(5):1818\u20131829","journal-title":"Diabetes."},{"issue":"8","key":"5032_CR24","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1210\/jc.2016-4003","volume":"102","author":"AK Steck","year":"2017","unstructured":"Steck AK, Xu P, Geyer S et al (2017) Can non-HLA single nucleotide polymorphisms help stratify risk in TrialNet relatives at risk for type 1 diabetes? J Clin Endocrinol Metab 102(8):2873\u20132880","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"5032_CR25","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.2337\/dc17-0238","volume":"40","author":"JP Krischer","year":"2017","unstructured":"Krischer JP, Lynch KF, Lernmark A et al (2017) Genetic and environmental interactions modify the risk of diabetes-related autoimmunity by 6 years of age: the TEDDY study. Diabetes Care 40(9):1194\u20131202","journal-title":"Diabetes Care"},{"issue":"7","key":"5032_CR26","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1007\/s00125-017-4258-7","volume":"60","author":"Petra M. P\u00f6ll\u00e4nen","year":"2017","unstructured":"Pollanen PM, Lempainen J, Laine AP et al (2017) Characterisation of rapid progressors to type 1 diabetes among children with HLA-conferred disease susceptibility. Diabetologia 60(7):1284\u20131293","journal-title":"Diabetologia"},{"issue":"23","key":"5032_CR27","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1016\/j.febslet.2011.04.032","volume":"585","author":"GL Burn","year":"2011","unstructured":"Burn GL, Svensson L, Sanchez-Blanco C, Saini M, Cope AP (2011) Why is PTPN22 a good candidate susceptibility gene for autoimmune disease? FEBS Lett 585(23):3689\u20133698","journal-title":"FEBS Lett"},{"issue":"3","key":"5032_CR28","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/pedi.12597","volume":"19","author":"MJ Redondo","year":"2018","unstructured":"Redondo MJ, Steck AK, Pugliese A (2018) Genetics of type 1 diabetes. Pediatr Diabetes 19(3):346\u2013353","journal-title":"Pediatr Diabetes"},{"issue":"7","key":"5032_CR29","doi-asserted-by":"publisher","first-page":"e11789","DOI":"10.1371\/journal.pone.0011789","volume":"5","author":"H Wang","year":"2010","unstructured":"Wang H, Jin Y, Linga Reddy MVP et al (2010) Genetically dependent ERBB3 expression modulates antigen presenting cell function and type 1 diabetes risk. PLoS One 5(7):e11789","journal-title":"PLoS One"},{"issue":"6","key":"5032_CR30","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.2337\/dc10-1661","volume":"34","author":"DM Wilson","year":"2011","unstructured":"Wilson DM, Xing D, Cheng J et al (2011) Persistence of individual variations in glycated hemoglobin: analysis of data from the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized trial. Diabetes Care 34(6):1315\u20131317","journal-title":"Diabetes Care"},{"issue":"4","key":"5032_CR31","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/j.1399-5448.2009.00566.x","volume":"11","author":"HB Mortensen","year":"2010","unstructured":"Mortensen HB, Swift PG, Holl RW et al (2010) Multinational study in children and adolescents with newly diagnosed type 1 diabetes: association of age, ketoacidosis, HLA status, and autoantibodies on residual beta-cell function and glycemic control 12 months after diagnosis. Pediatr Diabetes 11(4):218\u2013226","journal-title":"Pediatr Diabetes"},{"issue":"4","key":"5032_CR32","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.2337\/dc13-0604","volume":"37","author":"T Orban","year":"2014","unstructured":"Orban T, Bundy B, Becker DJ et al (2014) Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care 37(4):1069\u20131075","journal-title":"Diabetes Care"},{"issue":"23","key":"5032_CR33","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1001\/jama.2013.6285","volume":"309","author":"AG Ziegler","year":"2013","unstructured":"Ziegler AG, Rewers M, Simell O et al (2013) Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 309(23):2473\u20132479","journal-title":"JAMA"},{"issue":"6","key":"5032_CR34","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/eji.1830260616","volume":"26","author":"BO Roep","year":"1996","unstructured":"Roep BO, Duinkerken G, Schreuder GM, Kolb H, de Vries RR, Martin S (1996) HLA-associated inverse correlation between T cell and antibody responsiveness to islet autoantigen in recent-onset insulin-dependent diabetes mellitus. Eur J Immunol 26(6):1285\u20131289","journal-title":"Eur J Immunol"},{"issue":"8857","key":"5032_CR35","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/0140-6736(93)90940-I","volume":"341","author":"LC Harrison","year":"1993","unstructured":"Harrison LC, Honeyman MC, DeAizpurua HJ et al (1993) Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetes. Lancet 341(8857):1365\u20131369","journal-title":"Lancet."}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-019-05032-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-019-05032-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-019-05032-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T01:07:39Z","timestamp":1605834459000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-019-05032-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,21]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["5032"],"URL":"https:\/\/doi.org\/10.1007\/s00125-019-05032-3","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,21]]},"assertion":[{"value":"7 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there is no duality of interest associated with this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Duality of interest"}}]}}